Document:

Exhibit
4.4

 

THIS
SECURED CONVERTIBLE PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION
MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN
OPINION OF COUNSEL FOR THE HOLDER SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT OR RECEIPT OF
A NO-ACTION LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION.

 

SECURED
CONVERTIBLE PROMISSORY NOTE

 

	$                            	September ___, 2014
	 	Aliso Viejo, CA

 

For value received
CNS Response, Inc., a Delaware corporation (“Company”),
promises to pay to [_______] and its assigns (“Holder”) on or before February ___, 2016 (the “Maturity
Date”) the principal sum of $[__________] with interest on the outstanding principal amount at the rate of
five percent (5%) per annum, compounded annually based on a 365-day year. Interest shall commence with the date hereof and shall
continue on the outstanding principal until paid in full. The Holder shall have the right in its sole discretion to postpone the
Maturity Date repeatedly by providing written notice to the Company.

 

This Secured Convertible
Promissory Note (the “Note”) is one of a series of similar Secured Convertible Promissory Notes (collectively
with this Note, the “Notes”) issued by the Company pursuant to the terms of that certain Note Purchase Agreement
(the “Purchase Agreement”), dated as of September 22, 2014 (the “Agreement Date”), to the
persons and entities listed on Schedule A thereto (collectively, the “Holders”). Unless otherwise stated,
the Notes shall be pari passu in right of payment with respect to each other. All payments to each Holder of a Note shall be made
pro rata among the Holders based upon the aggregate unpaid principal amount of the Notes outstanding immediately prior to any such
payment. The Company shall not make, and no Holder shall accept, any payment except as shall be shared ratably between the Holders
so as to maintain as near as possible the amount of the debt owing under the Notes pro rata according to the Holders’ respective
proportionate interests in the amount of debt owed as of the date immediately prior to such payment or payments. If any Holder
obtains any payment (whether voluntary, involuntary, by application of offset or otherwise) of principal, interest or other amount
with respect to the Notes in excess of such Holder’s pro rata share of such payments obtained by all Holders, then the Holder
receiving such payment in excess of its pro rata share shall distribute to each of the other Holders an amount sufficient to cause
all Holders to receive their respective pro rata shares of any payment of principal, interest or other amount with respect to the
Notes.

 

1.          Payment.
All payments of interest and principal shall be in lawful money of the United States of America. All payments shall be applied
first to accrued interest, and thereafter to principal. Company may not prepay this Note prior to the Maturity Date without the
consent of the Majority Holders (as defined in the Purchase Agreement). No Notes owned by the Holder can be prepaid without the
Holder’s consent.

 

    	 

    	 

    

 

Qualified Financing
Conversion. In the event that Company issues and sells shares of its Equity Securities (as defined below) to investors (the
“Investors”) on or before the Maturity Date in an equity financing with total proceeds to the Company of not
less than $5,000,000 (excluding the conversion of the Notes, other convertible indebtedness or other debt) (a “Qualified
Financing”), then the outstanding principal balance and accrued interest of this Note (together, the “Conversion
Amount”) shall automatically convert in whole without any further action by the Holders into a number of shares of
Equity Securities equal to the greater of (i) the quotient of the Conversion Amount divided by a conversion price equal to 70%
of the price per share paid by the other purchasers purchasing the Equity Securities in the Qualified Financing, (ii) the quotient
of the Conversion Amount divided by a conversion price of $0.25 per one Equity Security (as adjusted for stock splits, stock dividends,
combinations or the like affecting the Equity Security, as applicable), and (iii) the lowest price per share paid by any purchaser
of shares of the Company’s common stock (“Common Stock”) purchased at any time following the Agreement
Date, but in no event less than $0.10 per share (as adjusted for stock splits, stock dividends, combinations or the like affecting
the Common Stock). Any resulting fraction of a share shall be rounded to the nearest whole share (with 0.5 being rounded up). By
receipt of this Note, the Holder acknowledges and agrees that it shall execute and deliver all documents that are reasonably required
by the Company to be executed by all of the Investors in the Qualified Financing. For purposes of this Note, the term “Equity
Securities” shall mean the Company’s Common Stock, preferred stock or any securities conferring the right to purchase
the Company’s Common Stock or preferred stock or securities convertible into, or exchangeable for (with or without additional
consideration), the Company’s Common Stock or preferred stock, except that such defined term shall not include (i) any security
granted, issued and/or sold by the Company to any employee, director or consultant in such capacity, or (ii) Notes issued pursuant
to the Purchase Agreement.

 

Voluntary Conversion.
Within the period of fifteen (15) days prior to the Maturity Date the Holder shall have an option to convert this Note into shares
of Common Stock, at a price equal to the lesser of (i) $0.25 per share (as adjusted for stock splits, stock dividends, combinations
or the like affecting the Common Stock), and (ii) the lowest price per share paid by any purchaser of shares of Common Stock of
the Company purchased at any time following the Agreement Date, but in no event less than $0.10 per share (as adjusted for stock
splits, stock dividends, combinations or the like affecting the Common Stock).

 

Change of Control.
If, prior to the earliest to occur of: (a) a Qualified Financing; (b) the conversion of this Note in accordance with Section 3;
or (c) the Maturity Date, the Company shall liquidate, dissolve, or enter into a transaction or series of related transactions
providing for a merger or consolidation of Company into or with an entity not previously affiliated with Company, or a sale, lease,
transfer or other disposition of all or substantially all of the assets of Company (unless, upon consummation of such merger, consolidation
or sale, the holders of voting securities of Company immediately prior to such transaction(s) own directly or indirectly more than
fifty percent (50%) of the voting power of the consolidated, surviving or acquiring corporation) (a “Change of Control”),
then the Holder shall have the right to have (i) one hundred and fifty percent (150%) of the outstanding principal amount of this
Note, plus (ii) accrued but unpaid interest on this Note, repaid in full upon the closing of such Change of Control. Notwithstanding
the foregoing, neither (x) a bona fide equity financing as a result of which this Note converts into Equity Securities in accordance
with Section 2 above; nor (y) a merger done in order to change the domicile of the Company shall be deemed a Change of Control.

 

    	 

    	 

    

 

Security Interest.
The full amount of this Note is secured by the Collateral (as defined in the Security Agreement) identified and described as security
therefore in the Security Agreement dated as of the date hereof executed by Company in favor of the Holders (the “Security
Agreement”). The Company hereby authorizes the Holder to file, or cause to be filed, any and all documents or instruments
that, in the Majority Holders’ (as defined in the Purchase Agreement) discretion, are required in order to perfect the security
interest granted hereby, including, without limitation, a UCC-1 financing statement, and, to the extent requested by the Holder,
the Company agrees to execute and deliver to the Holder any and all such documents or instruments.

 

2.          Maturity
Date; Extension. Unless this Note has been converted in accordance with the terms of Section 2, Section 3 or Section 4
above, the entire outstanding principal balance and all unpaid accrued interest shall become fully due and payable on the Maturity
Date; provided, however, the Holder shall have the right to unilaterally postpone the Maturity Date to any date of the Holder’s
choice upon written notice to the Company.

 

3.          Event
of Default. If there shall be any Event of Default (as defined below) hereunder, at the option and upon the declaration of
the Majority Holders (as defined in the Purchase Agreement) and upon written notice to the Company (which election and notice shall
not be required in the case of an Event of Default under Section 7(b) or 7(c)), this Note shall accelerate and all principal and
unpaid accrued interest shall become due and payable, and the Majority Holders (as defined in the Purchase Agreement) shall be
free to exercise any or all other rights and remedies available to the Holders under the Purchase Agreement, the Notes, the Security
Agreement and applicable law. The occurrence of any one or more of the following shall constitute an “Event of Default”:

 

The Company shall default
in the payment of any part of the principal or unpaid accrued interest on the Note for more than five (5) days after the Maturity
Date or at a date fixed by acceleration or otherwise;

 

The Company shall make
an assignment for the benefit of creditors, or shall admit in writing its inability to pay its debts as they become due, or shall
file a voluntary petition for bankruptcy, or shall file any petition or answer seeking for itself any reorganization, arrangement,
composition, readjustment, dissolution or similar relief under any present or future statute, law or regulation, or shall seek
or consent to or acquiesce in the appointment of any trustee, receiver or liquidator of the Company, or of all or any substantial
part of the properties of the Company, or the Company or its respective directors or majority stockholders shall take any action
looking to the dissolution, liquidation or winding-up of the Company; or

 

Within forty-five (45)
days after the commencement of any proceeding against the Company seeking any bankruptcy, reorganization, arrangement, composition,
readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, such proceeding
shall not have been dismissed, or within forty-five (45) days after the appointment without the consent or acquiescence of the
Company of any trustee, receiver or liquidator of the Company or of all or any substantial part of the properties of the Company,
such appointment shall not have been vacated.

 

    	 

    	 

    

 

In the event of any Event of Default hereunder,
Company shall pay all reasonable attorneys’ fees and court costs incurred by Holder in enforcing and collecting this Note.

 

4.          Miscellaneous.

 

The rights, powers and
remedies of the Holders under the Notes shall be in addition to all rights, powers and remedies given to the Holders by virtue
of any statute, rule of law, or other agreement, and shall be cumulative, and may be exercised successively or concurrently.

 

Company hereby waives
demand, notice, presentment, protest and notice of dishonor.

 

This Note shall be governed
by and construed under the laws of the State of California, as applied to agreements among California residents, made and to be
performed entirely within the State of California, without giving effect to conflicts of laws principles of the State of California,
or any other state.

 

Any term of this Note
may be amended (either retroactively or prospectively) with the written consent of the Company and the Majority Holders (as defined
in the Purchase Agreement).

 

All notices required
or permitted hereunder shall be in writing and shall be delivered in accordance with Section 4.3 of the Purchase Agreement.

 

[Remaining Page Left Intentionally Blank;
Signature Page Follows]

 

    	 

    	 

    

  

In
Witness Whereof, Company has duly executed and delivered this Note as of the date first set forth above.

 

	 	CNS RESPONSE, INC.
	 	 	 
	 	By:	 
	 	 	Name: 
	 	 	Title:Exhibit 10.89

 

NOTE PURCHASE AGREEMENT

 

This
NOTE PURCHASE Agreement (this “Agreement”) is made as of September 22, 2014 by and among CNS Response,
Inc., a Delaware corporation (the “Company”), and the investors listed on Schedule A hereto (each, an
“Investor” and together, the “Investors”).

 

Agreement

 

In consideration for
the mutual promises and covenants herein, the parties agree as follows:

 

Section
1 – Purchase and Sale of Notes

 

Purchase and Sale
of Notes. The Company has authorized the issuance and sale, in accordance with the terms hereof, of Secured Convertible Promissory
Notes in the original aggregate principal amount of up to $2,500,000 (the “Note Cap Amount”), substantially
in the form attached as Exhibit A hereto (individually, a “Note” and, collectively, the “Notes”).
On the terms and subject to the conditions set forth in this Agreement, at the Closings (as defined below) the Company agrees to
issue to each Investor, and each Investor agrees to purchase from the Company, a Note in the principal amount set forth on Schedule
A hereto for the aggregate consideration set forth opposite such Investor’s name on Schedule A hereto. The financing
pursuant to which the Company is issuing the Notes is hereinafter referred to as the “Financing”.

 

Closings.

 

(a)          Initial
Closing. The initial purchase and sale of the Notes shall take place at a closing (the “Initial Closing”)
which shall take place remotely via exchange of documents and signatures at such time and place as may be agreed to among the Company
and the Investors. At the Initial Closing, the Company shall deliver to each of the Investors purchasing Notes for cash at such
closing a Note in the face amount set forth opposite such Investor’s name on Schedule A under the column entitled
“Purchase Price / Principal Amount of Note (Initial Closing)” against receipt of a check subject to collection or a
wire transfer in immediately available funds of the purchase price, to an account designated by the Company.

 

(b)          Additional
Closings. The Company shall have the right, on one or more occasions, to hold additional closings (each, an “Additional
Closing”, and collectively with the Initial Closing, the “Closings”, and individually, a “Closing”),
pursuant to which it shall have the right to issue and sell additional Notes to additional Investors or existing Investors (provided
that no Additional Closings shall take place later than six (6) months after the Initial Closing). At each Additional Closing,
the Company shall deliver to each Investor purchasing Notes for cash at such closing a Note in the face amount of the purchase
price paid by such Investor for such Note, against receipt of a check subject to collection or a wire transfer in immediately available
funds of the purchase price, to an account designated by the Company. By receiving a Note at an Additional Closing, each Investor
receiving such Notes represents that its representations and warranties contained in Section 3 are true and correct as of the date
of such Additional Closing. The aggregate amount of Notes that may be issued at Closings hereunder shall in no event exceed the
Note Cap Amount. The Company shall have the right to update Schedule A in order to add information regarding Additional
Closings, which shall not be deemed to be an amendment to this Agreement.

 

    	 

    	 

    

 

 The obligation of each Investor to purchase and pay for
the Notes to be delivered at a Closing is, unless waived by such Investor, subject to the condition that the Company’s representations
and warranties contained in Section 2 are true, complete and correct on and as of such Closing date. The obligation of the Company
to sell and issue Notes to be delivered at a Closing is, unless waived by the Company, subject to the condition that the relevant
Investor’s representations and warranties contained in Section 3 are true, complete and correct on and as of the applicable
Closing date.

 

Security Agreement.
At the Initial Closing, the Company shall execute and deliver to the Investors a Security Agreement substantially in the form of
Exhibit B attached hereto (the “Security Agreement”).

 

Registration Rights
Agreement. At the Initial Closing, the Company shall execute and deliver to the Investors a Registration Rights Agreement substantially
in the form of Exhibit C attached hereto (the “Registration Rights Agreement”).

 

Section
2 - Representations and Warranties

of
the Company

 

The Company represents
and warrants to each Investor as follows:

 

2.1           Organization,
Good Standing and Qualification. The Company is a corporation duly organized and validly existing under the laws of the State
of Delaware. The Company has the requisite corporate power to own and operate its properties and assets and to carry on its business
as now conducted and as proposed to be conducted.

 

2.2           Authority
to Execute. The execution, delivery and performance by the Company of (i) this Agreement, (ii) the Notes to be issued pursuant
to the terms of this Agreement, (iii) the Security Agreement, (iii) the Registration Rights Agreement, and (iv) any financing statements
thereunder (collectively, the “Loan Documents”) are within the Company’s corporate powers, have been duly
authorized by all necessary corporate action, do not and will not conflict with any provision of law or organizational document
of the Company (including its Certificate of Incorporation or Bylaws) or of any agreement or contractual restrictions binding upon
or affecting the Company or any of its property and need no further stockholder or creditor consent.

 

2.3           No
Stockholder Approval Required. No approval of the Company’s stockholders is required for (i) the entry by the Company
into this Agreement, (ii) the issuance of the Notes contemplated by this Agreement, or (iii) the issuance of any shares of stock
upon conversion of the Notes.

 

    	1

    	 

    

  

2.4           Valid
Issuance. The shares of stock to be issued upon conversion of the Notes contemplated by this Agreement (the “Conversion
Securities” and together with the Notes, the “Securities”) will be, upon conversion and exercise in
accordance with the terms of the Notes, as applicable, validly issued, fully paid and nonassessable and free of restrictions on
transfer other than restrictions on transfer under the Loan Documents, the documents entered into by the investors and other parties
in the financing giving rise to repayment of the Notes, applicable state and federal securities laws and liens or encumbrances
created by or imposed by the Investor. Assuming the accuracy of the representations of the Investor in Section 3 of this Agreement,
the Securities will be issued in compliance with all applicable federal and state securities laws.

 

2.5           Binding
Obligation. This Agreement is, and the other Loan Documents when delivered hereunder will be, legal, valid and binding obligations
of the Company enforceable against the Company in accordance with their respective terms, subject, as to enforcement of remedies,
to applicable bankruptcy, insolvency, moratorium, reorganization and similar laws affecting creditors’ rights generally and
to general equitable principles.

 

2.6           Litigation.
Other than as disclosed in the Company’s SEC Reports (as defined below), no litigation or governmental proceeding is pending
or threatened against the Company which may have a materially adverse effect on the financial condition, operations or prospects
of the Company, and to the knowledge of the Company, no basis therefore exists.

 

2.7           Intellectual
Property. The Company owns or possesses sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights,
trade secrets, licenses, information and other proprietary rights and processes (“Intellectual Property”) necessary
for its business as now conducted and as presently proposed to be conducted, without any infringement of the rights of others.
Schedule B contains an accurate and complete list of all Intellectual Property owned by the Company or any of its subsidiaries.
The use by the Company or its subsidiaries of Intellectual Property owned or purported to be owned by the Company or its subsidiaries
and the general conduct and operations of the business of the Company and its subsidiaries does not violate, infringe, misappropriate
or misuse any Intellectual Property rights of any third party. To the knowledge of the Company, no third party is currently infringing,
misappropriating or otherwise violating, or has infringed or misappropriated or otherwise violated, rights of any of the Company
or its subsidiaries in any Intellectual Property owned, licensed, used, or held for us by the Company or its subsidiaries. There
are no outstanding options, licenses or agreements of any kind relating to the foregoing proprietary rights, nor is the Company
bound by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks,
trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes of any other person or
entity other than such licenses or agreements arising from the purchase of “off the shelf” or standard products.

 

2.8           SEC
Reports. The Company has timely filed all forms, reports, schedules, proxy statements, registration statements and other documents
(including all exhibits thereto) required to be filed by it with the Securities and Exchange Commission (the “SEC”)
pursuant to the federal securities laws and the SEC rules and regulations thereunder, together with all certifications required
pursuant to the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) (as they have been amended since the time
of their filing, including all exhibits thereto, the “SEC Reports”). Each of the SEC Reports complied in all
material respects with the applicable requirements of the Securities Act of 1933, as amended (the “Securities Act”)
and the Securities Exchange Act of 1934, as amended, the Sarbanes-Oxley Act and the rules and regulations of the SEC under all
of the foregoing. None of the SEC Reports contained any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading.

 

    	2

    	 

    

  

Section
3 - Representations and Warranties

of
the Investors

 

Each Investor represents
and warrants to the Company as follows:

 

3.1           Authorization;
Binding Obligations. The Investor has full power and authority to enter into this Agreement and each of the other Loan Documents
to which he, she or it is a party, and this Agreement and each other Loan Document constitutes a valid and legally binding obligation
of each Investor, enforceable against each Investor in accordance with its terms, subject, as to enforcement of remedies, to applicable
bankruptcy, insolvency, moratorium, reorganization and similar laws affecting creditors’ rights generally and to general
equitable principles.

 

3.2           Accredited
Investor. The Investor is an “accredited investor” within the meaning of SEC Rule 501 of Regulation D promulgated
under the Securities Act.

 

3.3           Investment
for Own Account. Each Investor represents that it (i) is acquiring the Securities solely for its own account and beneficial
interest for investment and not with a view to, or for resale in connection with, any distribution or public offering thereof within
the meaning of the Securities Act, and (ii) has no present intention of selling (in connection with a distribution or otherwise),
granting any participation in, or otherwise distributing the same, and does not presently have reason to anticipate a change in
such intention.

 

3.4           Information
and Sophistication. Without limiting the representations and warranties of the Company set forth in Section 3, each Investor
hereby: (a) acknowledges that it has received all the information it has requested from the Company and it considers necessary
or appropriate for deciding whether to acquire the Securities, (b) represents that it has had an opportunity to ask questions and
receive answers from the Company regarding the terms and conditions of the offering of the Securities and to obtain any additional
information necessary to verify the accuracy of the information given the Investor and (c) further represents that it has such
knowledge and experience in financial and business matters that it is capable of evaluating the merits and risk of this investment.

 

3.5           Ability
to Bear Economic Risk. Each Investor acknowledges that investment in the Securities involves a high degree of risk, and represents
that it is able, without materially impairing its financial condition, to hold the Securities for an indefinite period of time
and to suffer a complete loss of its investment.

 

3.6           U.S.
Person. Each Investor is a U.S. Person as defined under Regulation S under the Securities Act, as amended, which definitions
are attached hereto as Appendix I, or such Investor will make such representations and warranties, and agree to such covenants
and restrictions as set forth in Section 3.7 below.

 

3.7           Representations
and Warranties of Non-US Investors; Covenants of and Restrictions Thereon.

 

    	3

    	 

    

  

(a)          Representations
and Warranties. If Investor cannot represent and warrant that it is a U.S. Person (as defined in Appendix I hereto), such Investor
(a “Foreign Investor”) hereby represents and warrants to the Company as follows:

 

(i)          The
Securities being purchased are being acquired for investment for Foreign Investor’s own account, not as a nominee or agent,
and not for the account or benefit of, a U.S. Person (as defined in Appendix I hereto), and not with a view to the resale or distribution
of any part thereof in the United States (as defined in Appendix I hereto) or to a U.S. Person, and that Foreign Investor has no
present intention of selling, granting any participation in, or otherwise distributing such Securities.

 

(ii)         Foreign
Investor does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations
to such person or to any third person in the United States or to a U.S. Person, or any hedging transaction with any third person
in the United States or to a United States resident, with respect to any of the Securities.

 

(iii)        Foreign
Investor understands that the Securities are not registered under the Securities Act on the ground that the sale provided for in
this Agreement and the issuance of securities hereunder is exempt from registration under the Securities Act pursuant to Regulation
S thereof, and that the Company’s reliance on such exemption is predicated on the Foreign Investors’ representations
set forth herein.

 

(iv)        Foreign
Investor is a person or entity that is not a U.S. Person

 

(b)          Covenants.
Each Foreign Investor hereby agrees that:

 

(i)          Foreign
Investor will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy,
purchase or otherwise acquire or take a pledge of) any of the Securities purchased hereunder except in compliance with the Securities
Act, applicable blue sky laws, and the rules and regulations promulgated thereunder; provided that in a transaction exempt from
registration under the Securities Act, such Foreign Investor shall, prior to effecting such disposition, provide notice to the
Company of such proposed disposition and if reasonably requested by the Company submit to the Company an opinion of counsel in
form and substance reasonably satisfactory to the Company to the effect that the proposed transaction is in compliance with the
Securities Act.

 

    	4

    	 

    

  

(d)          Legend
Requirements. Each certificate representing the Securities issued to a Foreign Investor shall (unless otherwise permitted by
the provisions of the Agreement) be stamped or otherwise imprinted with a legend substantially similar to the following (in addition
to any legend required under applicable state securities laws or as provided elsewhere in this Agreement):

 

“THE SECURITIES REPRESENTED
HEREBY HAVE BEEN ACQUIRED PURSUANT TO REGULATION S OF THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT
BE SOLD, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE THEREWITH, PURSUANT TO A REGISTRATION UNDER
THE ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL
IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT
AND ANY APPLICABLE STATE SECURITIES LAWS. IN ADDITION, NO HEDGING TRANSACTION MAY BE CONDUCTED WITH RESPECT TO THESE SECURITIES
UNLESS SUCH TRANSACTIONS ARE IN COMPLIANCE WITH THE ACT.”

 

(e)          Stop-Transfer
Restrictions. The Company hereby agrees, for the benefit of the Investors, that it will not register any transfer of the Securities
not made in accordance with the provisions of Regulation S, pursuant to registration under the Securities Act, or pursuant to an
available exemption from registration.

 

3.8           Further
Assurances. Each Investor agrees and covenants that at any time and from time to time it will promptly execute and deliver
to the Company such further instruments and documents and take such further action as the Company may reasonably require in order
to carry out the full intent and purpose of this Agreement and to comply with state or federal securities laws or other regulatory
approvals.

 

Section
4 - Miscellaneous

 

4.1           Conditions
Precedent. The obligation of each Investor to consummate the transactions contemplated hereby is subject, at the option of
each Investor, to the fulfillment of the following conditions, any one or more of which may be waived by each Investor:

 

(a)          execution
of the Notes at each Closing;

 

(b)          approval
of the Company’s Board of Directors of the transactions contemplated hereby and all other actions necessary for the consummation
of the transactions contemplated hereby at the Initial Closing;

 

(d)          the
Company and each Investor shall have entered into the Registration Rights Agreement and the Security Agreement; and

 

(e)          the
Company shall have completed the filing of a UCC-1 financing statement with respect to the Collateral (as defined in the Security
Agreement) at the Initial Closing.

 

4.2           No
Waiver; Cumulative Remedies. No failure or delay on the part of any party to any Loan Document in exercising any right or remedy
under, or pursuant to, any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any such
right, remedy or power preclude other or further exercise thereof, or the exercise of any other right, remedy or power. The remedies
in the Loan Documents are cumulative and are not exclusive of any remedies provided by law.

 

    	5

    	 

    

  

4.2           Amendments
and Waivers. Except as otherwise expressly set forth in this Agreement, any term of this Agreement may be amended (either retroactively
or prospectively) with the written consent of (x) the Company and (y) and those Investors holding Notes whose aggregate principal
amount represents a majority of the total outstanding principal amounts of all then outstanding Notes under this Agreement, which
includes RSJ Private Equity uzavreny investicni fond a.s. (“RSJ”) for so long as RSJ is the holder of an outstanding
Note (collectively, the “Majority Holders”); provided that no such amendment may discriminate against a holder
of Notes in a manner different from the other holders without such holder’s written consent. Any amendment effected in accordance
with this Section 4.2 shall be binding upon each Investor, each future holder of Securities and the Company.

 

4.3           Notices.
Except as may be otherwise provided herein, all notices, requests, waivers and other communications made pursuant to this Agreement
shall be in writing and shall be conclusively deemed to have been duly given (a) when hand delivered to the other party; (b) when
sent by telecopier, facsimile or email transmission to the contact information set forth below if sent between 8:00 a.m. and 5:00
p.m. recipient’s local time on a Business Day (as defined below), or on the next Business Day if sent by telecopier, facsimile
or email transmission to the contact information set forth below if sent other than between 8:00 a.m. and 5:00 p.m. recipient’s
local time on a Business Day; (c) two Business Days after deposit in the U.S. mail with first class or certified mail receipt requested
postage prepaid and addressed to the other party at the address set forth below its name on the signature page hereto; or (d) the
next Business Day after deposit with a national overnight delivery service, postage prepaid, addressed to each of the parties as
set forth below its name on the signature page hereto with next Business Day delivery guaranteed, provided that the sending party
receives a confirmation of delivery from the delivery service provider:

 

If to the Company,
to:

 

CNS Response, Inc.

85 Enterprise, Suite
410

Attention: Paul Buck,
Chief Financial Officer

Fax: (866) 294-2611

eMail: pbuck@cnsresponse.com

 

If to an Investor,
to the contact information provided in Schedule A.

 

A party may change
or supplement its address for notice, or designate additional addresses, for purposes of this Section 4.3 by giving the other parties
written notice of the new address in the manner set forth above. For purposes of this Section 4.3, “Business Day”
shall mean any day which is not a Saturday or Sunday or a legal holiday on which banks are authorized or required to be closed
in Los Angeles, California or Czech Republic.

 

4.4           Costs
and Expenses. The Company and each Investor agree to be responsible for their own costs and expenses incurred in connection
with the preparation of the Loan Documents. If any litigation, contest, dispute, suit, proceeding or action is instituted between
or among any of the parties hereto regarding the enforcement or interpretation of this Agreement or any of the Exhibits hereto,
the prevailing party shall be entitled to reimbursement from the other party or parties for all reasonable expenses, costs, charges
and other fees (including legal fees) incurred in connection with or related to such dispute.

 

    	6

    	 

    

 

4.5           Governing
Law. The Loan Documents shall be governed by and construed in accordance with the laws of the State of California, without
regard to the conflicts of law provisions of the State of California or of any other state. The Company and each Investor consent
to personal jurisdiction in Orange County, California.

 

4.6           Severability.
If any term in this Agreement is held to be illegal or unenforceable, the remaining portions of this Agreement shall not be affected,
and this Agreement shall be construed and enforced as if this Agreement did not contain the term held to be illegal or unenforceable.

 

4.7           Binding
Effect; Assignment. The Loan Documents shall be binding upon and inure to the benefit of the Company and each Investor and
their respective successors and assigns. The Company may not assign its rights or interest under the Loan Documents without the
prior written consent of the Majority Holders.

 

4.8           Transfer
of Securities. Notwithstanding the legend required to be placed on the Securities by applicable law, no registration statement
or opinion of counsel shall be necessary: (a) for a transfer of Securities to the respective estate of each Investor or for a transfer
of Securities by gift, will or intestate succession of each Investor to his or her spouse or to the siblings, lineal descendants
or ancestors each Investor or his or her spouse, if the transferee agrees in writing to be subject to the terms hereof to the same
extent as if he or she were the original Investor hereunder; or (b) for a transfer of Securities pursuant to SEC Rule 144 or any
successor rule, or for a transfer of Securities pursuant to a registration statement declared effective by the SEC under the Securities
Act relating to the Securities.

 

4.9           Survival
of Representations and Warranties. The representations and warranties of the parties contained in or made pursuant to this
Agreement shall survive the execution and delivery of this Agreement indefinitely, and shall in no way be affected by any investigation
of the subject matter thereof made by or on behalf of the other parties.

 

4.10         California
Commissioner of Corporations. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH
THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF THE SECURITIES OR PAYMENT OR RECEIPT OF ANY PART
OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO THE QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM QUALIFICATIONS
BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY
CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.

 

[Remainder of Page Intentionally Left
Blank]

 

    	7

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as
of the date first written above.

 

	 	CNS RESPONSE, INC.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title: 

 

[SIGNATURE PAGE TO NOTE PURCHASE AGREEMENT]

 

    	 

    	 

    

  

	 	INVESTOR:
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

[SIGNATURE PAGE TO NOTE PURCHASE AGREEMENT]

 

    	 

    	 

    

 

SCHEDULE A

 

	Investor	 	 	Purchase Price / Principal Amount of Note
	 	 	 	 	 
	Name: 	 	 	 	 
	 	 	 	 	 
	Address:	 	 	 	 
	 	 	 	 	 
	 	 	 		 $________________________________
	 	 	 	 	 
	Fax:	 	 	 	 
	 	 	 	 	 
	Email: 	 	 	 	 
	 	 	 	 	 
	Tax ID:	 	 	 	 
	 	 	 	 	 
	TOTAL:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}]]